MPA
VRTX icon

Marvin & Palmer Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Marvin & Palmer Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,467
Closed -$3.01M – 40
2024
Q3 		$3.01M Sell
6,467
-215
-3% -$103K 2.52% 20
2024
Q2 		$2.79M Buy
6,682
+7
+0.1% +$3.04K 2.86% 22
2024
Q1 		$2.79M Sell
6,675
-394
-6% -$167K 2.77% 23
2023
Q4 		$2.88M Sell
7,069
-15,182
-68% -$5.61M 3.21% 14
2023
Q3 		$7.74M Sell
22,251
-4,124
-16% -$1.44M 5.02% 9
2023
Q2 		$9.28M Sell
26,375
-16,252
-38% -$5.48M 4.18% 15
2023
Q1 		$13.4M Buy
42,627
+3,472
+9% +$1.04M 6.77% 1
2022
Q4 		$11.3M Hold
39,155
– – 5.96% 1
2022
Q3 		$11.3M Sell
39,155
-1,901
-5% -$547K 6.96% 1
2022
Q2 		$11.6M Sell
41,056
-1,490
-4% -$399K 5.95% 1
2022
Q1 		$11.1M Buy
+42,546
New +$10.1M 5% 4
2020
Q4 		– Sell
-22,999
Closed -$6.26M – 38
2020
Q3 		$6.26M Sell
22,999
-2,549
-10% -$703K 3.3% 21
2020
Q2 		$7.42M Buy
25,548
+4,544
+22% +$1.23M 4.47% 9
2020
Q1 		$5M Buy
+21,004
New +$4.82M 4.78% 6
2013
Q3 		– Sell
-13,800
Closed -$1.1M – 83
2013
Q2 		$1.1M Buy
+13,800
New +$1.02M 0.6% 56

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Marvin & Palmer Associates's VRTX Position: Q4 2024 in Review

Marvin & Palmer Associates sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 6,467 shares — an estimated $3.01M sold.

Marvin & Palmer Associates first reported a position in VRTX in Q2 2013 and held it in 15 quarters. The position peaked at $13.4M in Q1 2023. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Marvin & Palmer Associates reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Marvin & Palmer Associates sold 6,467 Vertex Pharmaceuticals shares in Q4 2024, an estimated $3.01M.
  • Marvin & Palmer Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Marvin & Palmer Associates's Vertex Pharmaceuticals position peaked at $13.4M in Q1 2023.
  • 1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Marvin & Palmer Associates's 13F filing for Q4 2024, filed 7 Feb 2025.